Opinion|Videos|December 28, 2023
Future Perspectives in the Management of RCC
Author(s)Thomas E. Hutson, DO, PharmD, Kacie Ellis, RN
Experts share future perspectives on the treatment and management of patients with RCC.
Advertisement
Episodes in this series
Advertisement
Related to this article
Shankar Siva, MBBS, PhD, FRANZCR, discussed when to consider cytoreductive SABR in patients with metastatic kidney cancer responding to systemic therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
2
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
3
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
4
Evolving Perioperative Treatment Landscape for Resectable Gastric and Gastroesophageal Junction Cancers: A Q&A with Dr Nataliya Uboha
5